抗生物質耐性の市場規模、シェア、成長分析：疾患別、病原体別、薬剤クラス別、病原体の種類別、作用機序別、流通チャネル別、地域別 - 産業予測 2025～2032年

抗生物質耐性の世界市場規模は2023年に101億6,000万米ドルと評価され、2024年の110億8,000万米ドルから2032年には222億5,000万米ドルに成長し、予測期間（2025～2032年）のCAGRは9.1％で成長する見通しです。

世界の抗生物質耐性市場は、標準的な感染症治療の有効性を危うくするこの重大な健康危機をめぐる懸念の高まりにより、大幅な成長を遂げています。この危機を煽っている主な要因としては、抗生物質の過剰使用、誤用、ヘルスケア環境全体における不十分な感染予防対策などが挙げられます。さらに、新しい抗生物質のパイプラインが減少していることも、治療の限界を悪化させています。しかし、政府、ヘルスケア関係者、製薬企業の間で、この危機と闘うことが急務であるとの認識が高まっています。官民パートナーシップは抗生物質開発の革新を促進し、抗生物質スチュワードシップ・プログラムは使用を最適化するために強化されています。さらに、教育的な取り組みにより、ヘルスケア専門家や一般市民の意識が向上しています。ゲノミクスとプロテオミクスの進歩は、ファージ療法のような新たな治療法とともに、抗生物質耐性に効果的に対処するための課題と機会の両方を提示しています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

抗生物質耐性市場規模：疾患別

• 市場概要
• cUTI（複雑性尿路感染症）
• CDI（クロストリディオイデス・ディフィシル感染症）
• ABSSSI（急性細菌性皮膚および皮膚構造感染症）
• HABP（院内細菌性肺炎）
• CABP（市中肺炎）
• cIAI（複雑性腹腔内感染症）
• BSI（血流感染症）

抗生物質耐性市場規模：病原体別

• 市場概要
• 大腸菌
• 肺炎桿菌
• 緑膿菌
• 黄色ブドウ球菌

バウマニ

• 肺炎球菌
• インフルエンザ菌

ディフィシル

• E.フェシウム

抗生物質耐性市場規模：薬剤クラス別

• 市場概要
• オキサゾリジノン
• リポグリコペプチド
• テトラサイクリン
• 併用療法
• セファロスポリン
• その他

抗生物質耐性市場規模：病原体の種類別

• 市場概要
• アシネトバクター・バウマニ
• 緑膿菌
• 黄色ブドウ球菌
• 肺炎球菌
• その他

抗生物質耐性市場規模：作用機序別

• 市場概要
• タンパク質合成阻害剤
• 細胞壁合成阻害剤
• RNA合成阻害剤
• DNA合成阻害剤
• その他

抗生物質耐性市場規模：流通チャネル別

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局

抗生物質耐性市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022～2024年）

主要企業プロファイル

• GlaxoSmithKline（GSK）（United Kingdom）
• Pfizer（United States）
• AbbVie（United States）
• Merck & Co.（United States）
• Johnson & Johnson（United States）
• Novartis（Switzerland）
• Roche（Switzerland）
• AstraZeneca（United Kingdom）
• Eli Lilly and Company（United States）
• Bristol-Myers Squibb（United States）
• Bayer AG（Germany）
• Takeda Pharmaceutical Company（Japan）
• Amgen（United States）
• Teva Pharmaceutical Industries（Israel）
• Abbott Laboratories（United States）
• Bausch Health（Canada）
• Vaxcyte（United States）
• Sumitomo Pharma（Japan）
• Fujifilm Holdings Corporation（Japan）

結論と提言

Global Antibiotic Resistance Market size was valued at USD 10.16 billion in 2023 and is poised to grow from USD 11.08 billion in 2024 to USD 22.25 billion by 2032, growing at a CAGR of 9.1% during the forecast period (2025-2032).

The global antibiotic resistance market is witnessing substantial growth due to escalating concerns surrounding this critical health crisis, which jeopardizes the efficacy of standard infectious disease treatments. Key factors fueling this crisis include antibiotic overuse, misuse, and insufficient infection prevention measures across healthcare settings. Additionally, the diminishing pipeline of new antibiotics exacerbates treatment limitations. However, an increasing acknowledgment among governments, healthcare entities, and pharmaceutical companies underscores the urgency to combat antibiotic resistance. Public-private partnerships are fostering innovation in antibiotic development, while antibiotic stewardship programs are being enhanced to optimize usage. Furthermore, educational initiatives are improving awareness among healthcare professionals and the public. Advancements in genomics and proteomics, alongside emerging treatments like phage therapy, present both challenges and opportunities in addressing antibiotic resistance effectively.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antibiotic Resistance market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antibiotic Resistance Market Segments Analysis

Global Antibiotic Resistance Market is segmented by Disease, Pathogen, Drug Class, Pathogen Type, Mechanism of Action, Distribution Channel and region. Based on Disease, the market is segmented into cUTI (Complicated Urinary Tract Infections), CDI (Clostridioides difficile Infection), ABSSSI (Acute bacterial skin and skin structure infections), HABP (Hospital-acquired bacterial pneumonia), CABP (Community-acquired pneumonia), cIAI (Complicated intra-abdominal infection) and BSI (Bloodstream infection). Based on Pathogen, the market is segmented into E. coli, K. pneumoniae, P. aeruginosa, S. aureus, A. baumannii, S. pneumoniae, H. influenzae, C. difficile and E. faecium. Based on Drug Class, the market is segmented into Oxazolidinones, Lipoglycopeptides, Tetracyclines, Combination therapies, Cephalosporins and Others. Based on Pathogen Type, the market is segmented into Acinetobacter Baumannii, Pseudomonas Aeruginosa, Staphylococcus Aureus, Streptococcus Pneumoniae and Others. Based on Mechanism of Action, the market is segmented into Protein Synthesis Inhibitors, Cell Wall Synthesis Inhibitors, RNA Synthesis Inhibitors, DNA Synthesis Inhibitors and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Antibiotic Resistance Market

The surge in infections caused by antibiotic-resistant bacteria underscores the urgent need for the creation of effective treatment solutions. As conventional antibiotics lose their efficacy, there is an increasing demand for novel antibiotics and alternative therapeutic strategies to tackle these resistant strains. This pressing need drives extensive research and development efforts in the field, resulting in the discovery of new drugs and innovative treatment methods to counter antibiotic resistance. Furthermore, the growing public awareness regarding the severe implications of antibiotic resistance has prompted governments, healthcare organizations, and pharmaceutical companies to dedicate resources and invest in initiatives designed to address this critical issue.

Restraints in the Global Antibiotic Resistance Market

The global market for antibiotics faces significant challenges due to the relatively sparse pipeline of new antibiotic candidates in the face of escalating antibiotic resistance threats. The intricate and demanding process of developing novel antibiotics necessitates substantial investment, time, and specialized knowledge. Factors like the exorbitant costs of research and development, regulatory hurdles, and unattractive returns on investment have led to a downturn in antibiotic innovation. This scarcity of new antibiotics impairs the effective treatment of antibiotic-resistant infections, highlighting the pressing need for enhanced initiatives and incentives to promote and accelerate the development of novel antibiotics in the healthcare sector.

Market Trends of the Global Antibiotic Resistance Market

The Global Antibiotic Resistance market is witnessing a significant trend towards the exploration of alternative treatment modalities, driven by the escalating challenge of antibiotic resistance. As conventional antibiotics become less effective, researchers and healthcare professionals are increasingly focusing on innovative solutions such as phage therapy. This cutting-edge approach utilizes bacteriophages to selectively target and eradicate antibiotic-resistant bacteria, effectively addressing the limitations of traditional antibiotics while preserving beneficial microbiota. The growing recognition of the potential of phage therapy, coupled with increased investment in research and development, is set to reshape the landscape of infection management, promising improved patient outcomes in the face of rising resistance.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Antibiotic Resistance Market Size by Disease & CAGR (2025-2032)

• Market Overview
• cUTI (Complicated Urinary Tract Infections)
• CDI (Clostridioides difficile Infection)
• ABSSSI (Acute bacterial skin and skin structure infections)
• HABP (Hospital-acquired bacterial pneumonia)
• CABP (Community-acquired pneumonia)
• cIAI (Complicated intra-abdominal infection)
• BSI (Bloodstream infection)

Global Antibiotic Resistance Market Size by Pathogen & CAGR (2025-2032)

• Market Overview
• E. coli
• K. pneumoniae
• P. aeruginosa
• S. aureus

baumannii

• S. pneumoniae
• H. influenzae

difficile

• E. faecium

Global Antibiotic Resistance Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Oxazolidinones
• Lipoglycopeptides
• Tetracyclines
• Combination therapies
• Cephalosporins
• Others

Global Antibiotic Resistance Market Size by Pathogen Type & CAGR (2025-2032)

• Market Overview
• Acinetobacter Baumannii
• Pseudomonas Aeruginosa
• Staphylococcus Aureus
• Streptococcus Pneumoniae
• Others

Global Antibiotic Resistance Market Size by Mechanism of Action & CAGR (2025-2032)

• Market Overview
• Protein Synthesis Inhibitors
• Cell Wall Synthesis Inhibitors
• RNA Synthesis Inhibitors
• DNA Synthesis Inhibitors
• Others

Global Antibiotic Resistance Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Antibiotic Resistance Market Size & CAGR (2025-2032)

• North America (Disease, Pathogen, Drug Class, Pathogen Type, Mechanism of Action, Distribution Channel)
  • US
  • Canada
• Europe (Disease, Pathogen, Drug Class, Pathogen Type, Mechanism of Action, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease, Pathogen, Drug Class, Pathogen Type, Mechanism of Action, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease, Pathogen, Drug Class, Pathogen Type, Mechanism of Action, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease, Pathogen, Drug Class, Pathogen Type, Mechanism of Action, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• GlaxoSmithKline (GSK) (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vaxcyte (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Pharma (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Holdings Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations